<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30683" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tumor Necrosis Factor Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khaddour</surname>
            <given-names>Karam</given-names>
          </name>
          <aff>Rosalind Franklin University of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karam Khaddour declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30683.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A). There are also several off-label indications. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of tumor necrosis factors, so providers can direct patient therapy where they are indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanisms of action as a class and the specific effects of each agent in the TNF inhibitor class.</p></list-item><list-item><p>Identify the specific indications for each member of the TNF inhibitor class.</p></list-item><list-item><p>Outline the adverse event profile of TNF inhibitors.</p></list-item><list-item><p>Review the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care with TNF inhibitor therapy to improve patient outcomes for patients with conditions where these agents are indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30683&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30683">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30683.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Etanercept was the first anti-tumor necrosis factor (TNF) agent approved by the FDA to treat rheumatoid arthritis.&#x000a0;As of this writing, there are five different anti-TNF agents and ongoing expansion in their indications and use in various diseases.<xref ref-type="bibr" rid="article-30683.r1">[1]</xref><xref ref-type="bibr" rid="article-30683.r2">[2]</xref><xref ref-type="bibr" rid="article-30683.r3">[3]</xref><xref ref-type="bibr" rid="article-30683.r4">[4]</xref>&#x000a0;While anti-TNF agents have FDA approval for the treatment of several conditions (listed in media item 1), they are also used as off-label agents in various diseases, including graft-vs-host disease, pustular psoriasis, pyoderma gangrenosum, sarcoidosis, and Behcet disease.&#x000a0;</p>
      </sec>
      <sec id="article-30683.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tumor necrosis factor (TNF) plays a central role in the pathogenesis of several inflammatory conditions, including rheumatoid arthritis (RA). TNF is made intracellularly, mainly by activated macrophages. The precursor TNF is converted to soluble TNF after proteolysis by the TNF-converting enzyme. This soluble TNF then&#x000a0;oligomerizes and forms the biologically active homotrimer TNF. There are two types of TNF, which are very closely related, TNF-alpha and TNF-beta.&#x000a0;The activities of both TNFs are mediated through binding to the TNF receptors I and II (TNFRI and TNFRII),&#x000a0;which are present on almost all cell types (except erythrocytes).<xref ref-type="bibr" rid="article-30683.r5">[5]</xref><xref ref-type="bibr" rid="article-30683.r6">[6]</xref><xref ref-type="bibr" rid="article-30683.r7">[7]</xref></p>
        <p>The binding of TNF to TNFRI and TNFRII activates several signaling pathways, including transcription factor activation (nuclear factor-&#x003ba;B), proteases (caspases), and protein kinases (c-Jun N-terminal kinase,&#x000a0;MAP kinase). This signaling leads to activation of the target cell leading to the inflammatory and immune response by releasing several cytokines and apoptotic pathway initiation. Thus, the biological effects of TNF include activation of other cells (macrophages, T-cells, B-cells), proinflammatory cytokine production (IL-1, IL-6), chemokine production (IL-8, RANTES), expression of adhesion molecule (ICAM-1, E-selectin), inhibition of regulatory T-cells, RANK-ligand expression upregulation, matrix metalloproteinase production and induction of apoptosis. The differences in structure and mechanism of action of various anti-TNF agents appear in the second table accompanying this article.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-30683.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Etanercept</bold> administration is subcutaneous. The injection sites should be rotated and given at least one inch apart from previous injection sites.&#x000a0;</p>
        <p><bold>Infliximab</bold> administration is via an infusion. The infusion should occur over at least 2 hours and should not be co-administered with other biological immunosuppressive agents. Infusion-related reactions are possible, and if necessary, antihistamines, acetaminophen, and corticosteroids can be used as pre-medications to prevent these reactions.</p>
        <p><bold>Adalimumab</bold> administration is by subcutaneous injection. The injection sites should be rotated and away from previous injection sites.&#x000a0;</p>
        <p><bold>Certolizumab pegol</bold> is subcutaneously administered into the thigh or abdomen.&#x000a0;</p>
        <p><bold>Golimumab</bold> can be administered intravenously (IV) or subcutaneously. Infusions should occur over 30 minutes and should not be co-administered with other biological immunosuppressive agents. Subcutaneous injections use an autoinjector.</p>
      </sec>
      <sec id="article-30683.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Anti-TNF agents are generally well tolerated, with the common adverse effects being minor and not needing drug discontinuation. However, serious adverse effects have occurred, the most common being that of severe infections.</p>
        <p>Common adverse effects of all anti-TNF agents (occurring in more than 10% of patients)<xref ref-type="bibr" rid="article-30683.r8">[8]</xref><xref ref-type="bibr" rid="article-30683.r9">[9]</xref><xref ref-type="bibr" rid="article-30683.r4">[4]</xref><xref ref-type="bibr" rid="article-30683.r10">[10]</xref><xref ref-type="bibr" rid="article-30683.r11">[11]</xref>&#x000a0;include headaches, injection site reaction with the subcutaneous route, and infusion reaction with the intravenous route of administration, rashes, anemia, transaminitis (usually mild),&#x000a0;Upper respiratory tract infections, sinusitis, cough, pharyngitis, diarrhea, nausea, and abdominal pain.&#x000a0;</p>
        <p>
<bold>Infections</bold>
</p>
        <p>Serious infections are a significant and concerning adverse effect of anti-TNF agents and may include bacterial, fungal, viral, or atypical infections. These infections may be fatal. Infections are more common in patients receiving multiple immunosuppressive agents such as methotrexate or corticosteroids combined with anti-TNF agents. Reports exist of the reactivation of tuberculosis and viral hepatitis B and C, and it is a recommendation to screen individuals for these before initiating an anti-TNF agent.&#x000a0;In cases of reactivated latent tuberculosis, the reactivation occurs within the first few months of treatment with TNF-alpha inhibitors. Patients with latent tuberculosis should receive treatment with isoniazid or combination anti-tuberculosis agents before initiating anti-TNF agents. Patients living in areas with a higher incidence of certain fungal infections such as&#x000a0;blastomycosis, coccidioidomycosis, or histoplasmosis should have screening for these conditions before initiating anti-TNF agents. Lastly, clinicians should hold anti-TNF therapy in patients who develop a serious infection, and they can consider resuming treatment after complete recovery from the infection, provided the benefits of restarting the anti-TNF therapy outweighs the risk of recurrent infections in the particular patient.</p>
        <p>
<bold>Malignancies</bold>
</p>
        <p>The risk of malignancies, especially lymphomas, has been an area of concern and debate since the introduction of anti-TNF agents. Theoretically, anti-TNF agents can decrease the host defense mechanisms against malignancy by inhibiting TNF. FDA has placed a black box warning on all anti-TNF agents regarding possible association with malignancies, especially lymphomas. The analysis by the FDA in 2003 showed an occurrence of lymphomas in 6 out of more than 6,000 RA patients treated with anti-TNF agents while none in the placebo-treated patients. However, the risk of lymphomas is higher in RA patients (2&#x000a0;to 3 times, especially non-Hodgkins lymphoma), especially with advancing age, and in those with higher RA disease activity. Several subsequent studies have not shown an increased lymphoma risk in RA patients treated with anti-TNF agents compared to those treated with conventional DMARDs.<xref ref-type="bibr" rid="article-30683.r12">[12]</xref><xref ref-type="bibr" rid="article-30683.r13">[13]</xref><xref ref-type="bibr" rid="article-30683.r14">[14]</xref><xref ref-type="bibr" rid="article-30683.r15">[15]</xref>&#x000a0;Further studies may help clarify the lymphoma risk and the possible association with anti-TNF agents; caution is recommended in using anti-TNF agents in patients with prior malignancies and those with higher malignancy risk for other reasons.</p>
        <p>Several studies have shown a higher risk of non-melanoma skin cancers (up to two times) in patients receiving anti-TNF agents, and annual skin examinations should be considered in patients receiving anti-TNF agents.</p>
        <p>
<bold>Congestive Heart Failure</bold>
</p>
        <p>Initial studies of anti-TNF agents in patients with RA and congestive heart failure NYHA Class III or IV showed poor cardiac outcomes, including increased mortality, an increase in hospitalizations, and a worsening of CHF.<xref ref-type="bibr" rid="article-30683.r16">[16]</xref>&#x000a0;However, there are no reports of increased incidence of the development of congestive heart failure in association with anti-TNF agents.<xref ref-type="bibr" rid="article-30683.r17">[17]</xref><xref ref-type="bibr" rid="article-30683.r18">[18]</xref>&#x000a0;Clinicians should avoid anti-TNF agents in patients with severe congestive heart failure (NYHA Class III or IV) and use them cautiously in patients with mild congestive heart failure.</p>
        <p>
<bold>Drug-Induced Lupus</bold>
</p>
        <p>Up to 50% of patients receiving an anti-TNF agent can develop positive autoantibodies, including anti-nuclear antibody (ANA) and anti-Ds-DNA antibodies. However, the occurrence of drug-induced lupus is a rare occurrence (less than 1%). The common manifestations of drug-induced lupus from anti-TNF agents are&#x000a0;kin rash, thrombocytopenia, leukopenia, hypocomplementemia, and rarely hemolytic anemia.<xref ref-type="bibr" rid="article-30683.r19">[19]</xref>&#x000a0;The occurrence of drug-induced lupus from one anti-TNF agent is not always associated with drug-induced lupus from another anti-TNF agent.<xref ref-type="bibr" rid="article-30683.r20">[20]</xref>&#x000a0;Symptoms usually resolve within weeks to months of discontinuation of the drug, although autoantibodies may stay positive for several years.</p>
        <p>
<bold>Demyelinating Disorders</bold>
</p>
        <p>There are several reported cases of demyelinating disorders, including optic neuritis, multiple sclerosis (including exacerbation of underlying multiple sclerosis), myelitis, encephalitis, Guillain-Barre syndrome, transverse myelitis, and chronic inflammatory demyelinating polyneuropathy, in patients taking anti-TNF agents.<xref ref-type="bibr" rid="article-30683.r21">[21]</xref>&#x000a0;Anti-TNF agents should be avoided or used with extreme caution in patients with an underlying demyelinating disorder.</p>
        <p>
<bold>Skin Reactions</bold>
</p>
        <p>Rashes are not uncommon in patients receiving anti-TNF agents. The most common rash is a local injection site reaction/erythema, although other diffuse cutaneous reactions may also occur. An allergic reaction may lead to a diffuse drug rash. There are also reports of lupus-like rashes,&#x000a0;hypersensitivity vasculitis, urticaria, new-onset psoriasis, granuloma annulare, erythema multiforme, and cutaneous T-cell lymphoma.&#x000a0;</p>
        <p>
<bold>Pregnancy and Lactation</bold>
</p>
        <p>No controlled trials have taken place to assess the safety of anti-TNF agents in pregnancy or lactation. Anti-TNF agents have been labeled as Class B pregnancy risk by the FDA. Several registries have shown a low risk of major congenital defects with the use of anti-TNF agents in pregnancy, not significantly higher in the disease-matched comparison cohort, and with no birth-defect patterns. Researchers observed no fetal harm or malformations in animal trials.&#x000a0;Except for certolizumab, all other anti-TNF agents cross the placenta, exposing the infant to the anti-TNF agent. Anti-TNF agent use in pregnancy should be a consideration only if there is a clear and strong indication.</p>
        <p>Similarly, there is no data regarding the use of anti-TNF agents in lactating females. Anti-TNF agents have been found in the human milk at less than 1% of the maternal serum concentration, and there are no reports of adverse effects of anti-TNF agents in breastfed infants or on milk production. It is not known if the infant absorbs the anti-TNF agents at these low concentrations in human milk or not. Until more data is available, clinicians should avoid anti-TNF agents in lactating females.</p>
      </sec>
      <sec id="article-30683.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients should not receive anti-TNF agents if there is a history of hypersensitivity reaction to the agent. Clinicians should not initiate and should discontinue ongoing therapy in the presence of an active infection or sepsis. Anti-TNF agents are also contraindicated in patients with NYHA Class III or IV congestive heart failure.</p>
        <p>While conventional non-biologic DMARDs such as methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine can be used in combination with anti-TNF agents, concomitant use of an anti-TNF agent with another biological immunosuppressive agent is contraindicated.</p>
      </sec>
      <sec id="article-30683.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Testing for active/latent tuberculosis and viral hepatitis B and C should occur before initiating anti-TNF agents. Clinicians should monitor patients&#x000a0;for signs of infection before, during, and after treatment.<xref ref-type="bibr" rid="article-30683.r10">[10]</xref><xref ref-type="bibr" rid="article-30683.r22">[22]</xref>&#x000a0;Additionally, complete blood counts and liver function tests&#x000a0;are necessary at baseline and monitored closely (at least every 3 to 6 months). Despite the high incidence of autoantibody positivity, it is not necessary to monitor patients on anti-TNF agents for the development of ANA or anti-Ds-DNA antibodies routinely due to the low incidence of symptoms of drug-induced lupus despite the positive autoantibodies. However, patients who develop symptoms of SLE or another autoimmune disease&#x000a0;should undergo this testing to help establish a diagnosis.</p>
        <p>Patients on anti-TNF agents should not receive any live immunizations, and patients should be up to date with vaccinations before initiating anti-TNF agents.</p>
        <p>Anti-TNF agents may be associated with a higher risk in patients undergoing major surgeries such as hip or knee replacement. The recommendation is to hold these medications one week and one dosing cycle before the surgery. They can be resumed two weeks after the surgery, provided there is no infection and incisions are healing well.<xref ref-type="bibr" rid="article-30683.r23">[23]</xref></p>
      </sec>
      <sec id="article-30683.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As with many medications, there must be interprofessional communication regarding the dispensing and monitoring of the various TNF alpha inhibitors. With inflammatory bowel disease and other autoimmune disorders, physicians and pharmacists must&#x000a0;be aware of the treatment guidelines when deciding to treat with TNF alpha inhibitors as opposed to other treatment options.<xref ref-type="bibr" rid="article-30683.r24">[24]</xref> Pharmacists, nurses, and physicians must work together as an interprofessional team to ensure that proper dosing and dispensing protocols are in place and be aware of the possibility of adverse effects.<xref ref-type="bibr" rid="article-30683.r25">[25]</xref></p>
        <p>For example, infliximab requires an infusion over a specified period, cannot be combined with other medications, and there is the possibility of infusion-related reactions. Nursing should be well educated about these facts and coordinate with the pharmacy regarding the dosing and administration. Pharmacy always needs to be involved in dose verification and closely monitor drug interactions, informing the physician if there are any concerns. The healthcare team must work together to ensure patient safety, and the use of electronic medical records may be useful in this setting.<xref ref-type="bibr" rid="article-30683.r26">[26]</xref></p>
        <p>Additionally, the interprofessional healthcare team should be aware of the evolving nature of biosimilars as they relate to prescribing TNF alpha inhibitors and keep up-to-date on the available prescribing options.<xref ref-type="bibr" rid="article-30683.r27">[27]</xref> Here again, the pharmacist is responsible for coordinating with the physicians to appraise them of the latest therapy options. Only through this type of interprofessional collaboration and communication can anti-TNF therapy obtain optimal therapeutic results with minimal adverse events. [Level 5]</p>
      </sec>
      <sec id="article-30683.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30683&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30683">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30683/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30683">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30683.s10">
        <fig id="article-30683.image.f1" position="float" orientation="portrait">
          <caption>
            <p>FDA-approved indications of various Anti-TNF agents. Created and contributed by Pankaj Bansal, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TNFindications" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30683.s11">
        <fig id="article-30683.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Description of structure and mechanism of action of various Anti-TNF agents. Created and contributed by Amandeep Goyal, MD and Pankaj Bansal, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TNF__structure__and__action" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30683.s12">
        <title>References</title>
        <ref id="article-30683.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meroni</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cattaneo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valesini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.</article-title>
            <source>Autoimmun Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>812</fpage>
            <page-range>812-29</page-range>
            <pub-id pub-id-type="pmid">25985765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Komaki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kudaravalli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Micic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sakuraba</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-&#x003b1; agents in rheumatic diseases; A systematic review and meta-analysis.</article-title>
            <source>J Autoimmun</source>
            <year>2017</year>
            <month>May</month>
            <volume>79</volume>
            <fpage>4</fpage>
            <page-range>4-16</page-range>
            <pub-id pub-id-type="pmid">28209290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubbert-Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atzeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Masala</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Caporali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montecucco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sarzi-Puttini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?</article-title>
            <source>Autoimmun Rev</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">29108829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haraoui</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Differentiating the efficacy of the tumor necrosis factor inhibitors.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>5 Suppl1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">15852248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maini</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?</article-title>
            <source>Annu Rev Immunol</source>
            <year>2001</year>
            <volume>19</volume>
            <fpage>163</fpage>
            <page-range>163-96</page-range>
            <pub-id pub-id-type="pmid">11244034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Tumor necrosis factor blockade: mechanism of action.</article-title>
            <source>J Investig Dermatol Symp Proc</source>
            <year>2007</year>
            <month>May</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">17502861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roach</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bean</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Demangel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>France</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Briscoe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.</article-title>
            <source>J Immunol</source>
            <year>2002</year>
            <month>May</month>
            <day>01</day>
            <volume>168</volume>
            <issue>9</issue>
            <fpage>4620</fpage>
            <page-range>4620-7</page-range>
            <pub-id pub-id-type="pmid">11971010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Armuzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>769</fpage>
            <page-range>769-79</page-range>
            <pub-id pub-id-type="pmid">23453887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheifetz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smedley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plevy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The incidence and management of infusion reactions to infliximab: a large center experience.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>98</volume>
            <issue>6</issue>
            <fpage>1315</fpage>
            <page-range>1315-24</page-range>
            <pub-id pub-id-type="pmid">12818276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thalayasingam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF therapy.</article-title>
            <source>Best Pract Res Clin Rheumatol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-67</page-range>
            <pub-id pub-id-type="pmid">22137924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreland</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bulpitt</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ruderman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Arkfeld</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Garrison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Burge</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Blosch</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.</article-title>
            <source>Ann Intern Med</source>
            <year>1999</year>
            <month>Mar</month>
            <day>16</day>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>478</fpage>
            <page-range>478-86</page-range>
            <pub-id pub-id-type="pmid">10075615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1433</fpage>
            <page-range>1433-9</page-range>
            <pub-id pub-id-type="pmid">17469100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baecklund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Granath</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Geborek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fored</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Backlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertilsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>C&#x000f6;ster</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jacobsson</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lysholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rantap&#x000e4;&#x000e4;-Dahlqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saxne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feltelius</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>May</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>648</fpage>
            <page-range>648-53</page-range>
            <pub-id pub-id-type="pmid">18467516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Matucci-Cerinic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pavelka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heatley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>11</issue>
            <fpage>1895</fpage>
            <page-range>1895-904</page-range>
            <pub-id pub-id-type="pmid">21885875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>9</issue>
            <fpage>2886</fpage>
            <page-range>2886-95</page-range>
            <pub-id pub-id-type="pmid">17729297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Fasanmade</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Willerson</surname>
                <given-names>JT</given-names>
              </name>
              <collab>Anti-TNF Therapy Against Congestive Heart Failure Investigators</collab>
            </person-group>
            <article-title>Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.</article-title>
            <source>Circulation</source>
            <year>2003</year>
            <month>Jul</month>
            <day>01</day>
            <volume>107</volume>
            <issue>25</issue>
            <fpage>3133</fpage>
            <page-range>3133-40</page-range>
            <pub-id pub-id-type="pmid">12796126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>01</day>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>305</fpage>
            <page-range>305-11</page-range>
            <pub-id pub-id-type="pmid">14984815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Busti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists.</article-title>
            <source>Rheumatol Int</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-73</page-range>
            <pub-id pub-id-type="pmid">17028862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Solhjoo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Drug-Induced Lupus Erythematosus</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">28722919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.</article-title>
            <source>Int J Dermatol</source>
            <year>2011</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>619</fpage>
            <page-range>619-25</page-range>
            <pub-id pub-id-type="pmid">21506984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Baer</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Guillain-Barr&#x000e9; and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.</article-title>
            <source>Arthritis Rheum</source>
            <year>2006</year>
            <month>May</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>1429</fpage>
            <page-range>1429-34</page-range>
            <pub-id pub-id-type="pmid">16645971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amital</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF therapy: safety aspects of taking the risk.</article-title>
            <source>Autoimmun Rev</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>563</fpage>
            <page-range>563-8</page-range>
            <pub-id pub-id-type="pmid">21570495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Springer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abdel</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Dasa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gewurz-Singer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mandl</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Mont</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sculco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sporer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stryker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brause</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Gililland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hurley-Rosenblatt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Losina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>MacKenzie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1111</fpage>
            <page-range>1111-1124</page-range>
            <pub-id pub-id-type="pmid">28620917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Feagan</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Fedorak</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kamm</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Regueiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Targan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.</article-title>
            <source>Gastroenterology</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>312</fpage>
            <page-range>312-39</page-range>
            <pub-id pub-id-type="pmid">17631151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Keshav</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Medical management of Crohn's disease.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>May</month>
            <day>10</day>
            <volume>336</volume>
            <issue>7652</issue>
            <fpage>1062</fpage>
            <page-range>1062-6</page-range>
            <pub-id pub-id-type="pmid">18467414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharpless</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Del Rosario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Molle-Rios</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hilmas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Use of Electronic Health Record Tools to Facilitate and Audit Infliximab Prescribing.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">29491748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30683.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chingcuanco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Bioequivalence of Biosimilar Tumor Necrosis Factor-&#x003b1; Inhibitors Compared With Their Reference Biologics: A Systematic Review.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>Oct</month>
            <day>18</day>
            <volume>165</volume>
            <issue>8</issue>
            <fpage>565</fpage>
            <page-range>565-574</page-range>
            <pub-id pub-id-type="pmid">27479870</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
